Sleep and circadian science remain underrecognized frontiers for disease prevention
Two institutions separated by an ocean — Monash University in Melbourne and Brigham and Women's Hospital in Boston — have renewed a research alliance that quietly asks one of medicine's most neglected questions: what does sleep have to do with everything else that makes us sick? Fifteen years and 250 publications into their collaboration, they are now turning toward wearable technology and multi-centre clinical trials, betting that the rhythms of the body, long overlooked in preventive medicine, may hold answers to chronic diseases that pharmaceutical approaches alone have not resolved.
- Sleep and circadian science remain the underrecognized frontier of preventive medicine, even as diabetes, dementia, and cardiovascular disease continue to overwhelm healthcare systems worldwide.
- The renewal of this partnership signals urgency — not crisis, but the quiet pressure of mounting evidence that behavioral patterns preceding disease are going unmonitored and unaddressed at scale.
- Wearable devices are now capable of capturing the kind of granular, real-world behavioral data — movement, sleep, rhythm — that clinical settings never could, opening a new lane for affordable, population-wide intervention.
- Multi-centre clinical trials are being planned to map how sleep, physical activity, nutrition, and mental health interact, with the goal of identifying patterns that can be modified before disease takes hold.
- The Monash Boston Hub in Kendall Square positions this science at the intersection of academic research, biotech investment, and clinical infrastructure — accelerating the journey from laboratory insight to real-world treatment.
In June 2026, Monash University and Brigham and Women's Hospital marked the renewal of a research partnership that began in 2009 and has since produced more than 250 peer-reviewed publications. The ceremony in Boston was quiet by the standards of institutional announcements, but the ambition behind it was not.
The collaboration has always occupied an unusual space in medical research — one focused on sleep and circadian rhythms, fields that have long been treated as secondary concerns despite growing evidence of their role in chronic disease. Professor Emmanuel Stamatakis of Monash's Turner Institute for Brain and Mental Health frames the work as correcting a gap: while nutrition and physical activity have become established pillars of prevention, sleep science has lagged behind. Recent Monash research has already shown that brief daily bursts of movement, the kind a wearable device can detect, may help prevent Type 2 diabetes — a finding that points toward the kind of scalable, behavioral intervention the partnership now wants to pursue more broadly.
The next phase will involve multi-centre clinical trials examining how sleep, activity, nutrition, and mental health interact to either protect against or accelerate conditions like diabetes, cardiovascular disease, and dementia. The tools will be digital — wearables and behavioral monitoring — chosen for their potential to work at population scale and at lower cost than pharmaceutical approaches.
The institutions bring complementary strengths. Monash operates Australia's largest clinical trial network, with more than 7,000 hospital beds and 3,000 general practitioners. Brigham and Women's, a Harvard teaching affiliate and founding member of Massachusetts' largest healthcare provider, offers scientific depth and clinical reach on the American side. Their shared office in Kendall Square — the Monash Boston Hub — connects this research ecosystem to biotech firms and investors, shortening the distance between discovery and practice.
Leading the collaboration are Professor Shantha Rajaratnam from Monash and Dr. Charles Czeisler from Brigham and Harvard, whose combined work has advanced understanding of light biology, shift work, sleep apnea, and the links between disrupted sleep and mental and cardiovascular health. What the renewed partnership ultimately represents is a wager — that the behavioral patterns preceding chronic disease are readable, modifiable, and worth pursuing before the disease itself arrives.
Two major research institutions—Monash University in Australia and Brigham and Women's Hospital in Boston—have renewed a partnership that has quietly become one of the more productive collaborations in sleep science. The announcement came in June at a ceremony in Boston, marking the continuation of work that began in 2009 and has already generated more than 250 peer-reviewed publications.
The partnership sits at the intersection of several converging interests in modern medicine: the recognition that sleep and circadian rhythms remain largely neglected in how we think about preventing chronic disease, and the growing capability of wearable technology to track behavior at scale. The two institutions are now planning multi-centre clinical trials that will investigate how sleep, physical activity, nutrition, and mental health interact to either protect against or accelerate the onset of conditions like Type 2 diabetes, cardiovascular disease, and dementia.
Professor Emmanuel Stamatakis, who directs the Monash Brain Park at the Turner Institute for Brain and Mental Health, frames the work as addressing a gap in how medicine approaches prevention. While physical activity and nutrition have become established pillars of preventive health, sleep and circadian science remain underrecognized despite mounting evidence of their importance. Recent research from Monash has shown that even brief bursts of daily movement—the kind captured by wearable devices—may help prevent Type 2 diabetes. The partnership aims to discover similar behavioral patterns that could be monitored and modified using simple, scalable digital tools.
The collaboration brings together complementary strengths. Monash has built Australia's largest clinical trial network, spanning more than 7,000 hospital beds and engaging over 3,000 general practitioners. Brigham and Women's Hospital is a founding member of Mass General Brigham, Massachusetts' largest healthcare provider, and serves as a teaching affiliate of Harvard Medical School. Together, they represent research ecosystems with both the scientific depth and the clinical infrastructure to move discoveries from the laboratory into practice.
Professor Shantha Rajaratnam, who leads the partnership from Monash's side alongside Dr. Charles Czeisler from Brigham and Harvard, emphasizes the global scope of what the collaboration has already accomplished. Over nearly two decades, the partnership has produced advances in understanding light biology, the health effects of shift work, obstructive sleep apnea, and the links between sleep disruption and mental health, cardiovascular disease, and dementia. The new phase will push toward more personalized approaches to both prevention and treatment.
The partnership is anchored in the Monash Boston Hub, a dedicated office in Kendall Square that connects Monash's research capabilities with biotech companies, pharmaceutical firms, and investors in the United States. According to Robyn Ward, Monash's Deputy Vice-Chancellor for Research and Enterprise, the Hub serves as a gateway for American researchers and health systems to access Monash's clinical trial and innovation ecosystem. The logic is straightforward: by combining Monash's strength in translational research and clinical trials with the scientific and clinical leadership of Brigham and Harvard, the institutions can accelerate the path from discovery to real-world treatment.
What makes this partnership noteworthy is not just its productivity but its focus on prevention through behavioral intervention rather than pharmaceutical treatment. Wearable devices and digital health tools offer a way to monitor and modify behavior at a population scale, potentially at lower cost than traditional medical interventions. As chronic diseases continue to impose enormous burdens on healthcare systems worldwide, the ability to identify and intervene in the early behavioral patterns that precede disease could reshape how medicine approaches prevention.
Citas Notables
Sleep and circadian science present underrecognised frontiers for the prevention of chronic disease and medical innovation that demand urgent attention— Professor Emmanuel Stamatakis, Director of Monash Brain Park
By combining Monash's strengths in translational research and clinical trials with the scientific and clinical leadership of Brigham and Women's Hospital and Harvard Medical School, we are creating new opportunities to accelerate discovery and improve patient outcomes— Professor Robyn Ward, Monash Deputy Vice-Chancellor for Research and Enterprise
La Conversación del Hearth Otra perspectiva de la historia
Why does sleep science matter so much right now? It seems like we've known for decades that sleep is important.
We have, but we've treated it as peripheral to medicine. Doctors focus on drugs and procedures. Sleep gets filed under lifestyle advice. What's changed is that we now have wearable devices that can actually track sleep patterns at scale, and the evidence linking sleep disruption to diabetes, dementia, and heart disease has become impossible to ignore.
So this partnership is really about using technology to make prevention actionable?
Exactly. It's not just knowing that sleep matters. It's being able to measure it in thousands of people, identify patterns, and test whether small interventions—changes in light exposure, activity timing, sleep scheduling—can actually prevent disease before it starts.
The partnership has been running since 2009. What's different about renewing it now?
The infrastructure has matured. Monash has built the largest clinical trial network in Australia. Brigham has Harvard's research apparatus behind it. Now they can actually run the multi-centre trials that would have been impossible fifteen years ago. The technology is also better—wearables are more accurate and more widely adopted.
Is there a risk that this becomes just another way to medicalize normal life? Turning sleep into data points?
That's a fair concern. But the alternative is the status quo, where we wait for people to develop diabetes or dementia and then treat it expensively. If wearable data can identify someone at risk and a simple behavioral change prevents disease, that's a different calculus.
What would success look like for this partnership?
A clinical trial showing that a scalable intervention—maybe something as simple as adjusting light exposure or activity timing based on wearable data—can meaningfully reduce the incidence of Type 2 diabetes or delay cognitive decline. Something that works, that's affordable, and that can be deployed across health systems.